Her2-low/ HRR proficient early triple negative breast cancer is characterized by good prognosis

被引：0

作者：

Pellegrino, B. ^{[1
]}

Tornali, C. ^{[2
]}

Lazzarin, A. ^{[3
]}

Cotelli, B. ^{[2
]}

Ingallinella, A. ^{[2
]}

Campanini, N. ^{[4
]}

Tommasi, C. ^{[5
]}

Coriano, M. ^{[6
]}

Serra, O. ^{[7
]}

Michiara, M. ^{[8
]}

Boggiani, D. ^{[9
]}

Schirone, A. ^{[10
]}

Casarini, C. ^{[11
]}

Cretella, E. ^{[12
]}

Zoppoli, G. ^{[13
,14
]}

Lambertini, M. ^{[15
]}

Botosso, M. ^{[16
]}

Cortesi, L. ^{[17
]}

Silini, E. M. ^{[18
]}

Musolino, A. ^{[19
]}

机构：

[1] Osped Maggiore Parma, Oncol Dept, Parma, Italy

[2] Univ Parma, Oncol, Parma, Italy

[3] Univ Parma, Med Oncol Dept, Parma, Italy

[4] Univ Parma, Fac Med & Chirurg, Pathol, Parma, Italy

[5] Univ Parma, Fac Med & Chirurg, Med Oncol & Breast Unit, Parma, Italy

[6] Azienda Osped Univ Parma, Oncol, Parma, Italy

[7] Univ Parma, Fac Med & Chirurg, Oncol, Parma, Italy

[8] Osped Maggiore Parma, Oncol, Parma, Italy

[9] Univ Hosp Parma, Oncol, Parma, Italy

[10] Arcispedale SantAnna AOU Ferrara, Med, Ferrara, Italy

[11] Nuovo Osped Sassuolo, Oncol, Sassuolo, Italy

[12] Osped Cent Bolzano ASDAA SABES, Oncol Dept, Bolzano, Italy

[13] Univ Genoa, Dept Internal Med, Genoa, GE, Italy

[14] Osped Policlin San Martino IRCCS, DiMI, Genoa, GE, Italy

[15] IRCCS AOU San Martino, IST Ist Nazl Ric Canc, Oncol, Genoa, Italy

[16] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy

[17] Azienda Osped Univ Policlin Modena, Haematol & Oncol Dept, Modena, Italy

[18] Univ Parma, Pathol, Parma, Italy

[19] Univ Parma, Fac Med & Chirurg, Dept Med, Parma, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.212

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

269P

引用

页码：S328 / S329

页数：2

共 50 条

[41] Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
Hu, Xi'e
Yang, Ping
Chen, Songhao
Wei, Gang
Yuan, Lijuan
Yang, Zhenyu
Gong, Li
He, Li
Yang, Lin
Peng, Shujia
Dong, Yanming
He, Xianli
Bao, Guoqiang
BREAST CANCER RESEARCH, 2023, 25 (01)
[42] Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low
Xi′e Hu
Ping Yang
Songhao Chen
Gang Wei
Lijuan Yuan
Zhenyu Yang
Li Gong
Li He
Lin Yang
Shujia Peng
Yanming Dong
Xianli He
Guoqiang Bao
Breast Cancer Research, 25
[43] The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
Schreiber, Anna R.
O'Bryant, Cindy L.
Kabos, Peter
Diamond, Jennifer R.
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (10) : 1061 - 1069
[44] Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
Xu, Hangcheng
Han, Yiqun
Wu, Yun
Wang, Yan
Li, Qing
Zhang, Pin
Yuan, Peng
Luo, Yang
Fan, Ying
Chen, Shanshan
Cai, Ruigang
Li, Qiao
Ma, Fei
Xu, Binghe
Wang, Jiayu
FRONTIERS IN ONCOLOGY, 2022, 12
[45] Epidemiology and Prognosis of HER2-Low Breast Cancer (BC) in the National Cancer Data Base (NCDB)
Peiffer, Daniel
Howard, Frederick M.
Chen, Nan
Hahn, Olwen M.
Nanda, Rita
Olopade, Olufunmilayo I.
Huo, Dezheng
CANCER RESEARCH, 2023, 83 (05)
[46] Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)
Domergue, C.
Martin, E.
Lemarie, C.
Jezequel, P.
Frenel, J-S.
Augereau, P.
Campone, M.
Patsouris, A.
ANNALS OF ONCOLOGY, 2021, 32 : S428 - S429
[47] Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer
Lv, Huimin
Yan, Min
Zhang, Mengwei
Niu, Limin
Zeng, Huiai
Sun, Huihui
Zhao, Shengnan
Wang, Jing
CANCER RESEARCH, 2024, 84 (09)
[48] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Wei Wang
Tingting Zhu
Hao Chen
Yongzhong Yao
Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
[49] HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
van den Ende, Nadine S.
Smid, Marcel
Timmermans, Annemieke
van Brakel, Johannes B.
Hansum, Tim
Foekens, Renee
Trapman, Anita M. A. C.
Heemskerk-Gerritsen, Bernadette A. M.
Jager, Agnes
Martens, John W. M.
van Deurzen, Carolien H. M.
SCIENTIFIC REPORTS, 2022, 12 (01)
[50] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Wang, Wei
Zhu, Tingting
Chen, Hao
Yao, Yongzhong
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681

← 1 2 3 4 5 →